Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TransThera Sciences (Nanjing). Inc. ( (HK:2617) ) has shared an announcement.
TransThera Sciences (Nanjing), Inc. has announced a collaboration with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors, a preclinical asset aimed at treating multiple diseases. This agreement grants Neurocrine exclusive rights outside Greater China, while TransThera retains rights within Greater China. The deal includes potential milestone payments up to $881.5 million, reflecting significant financial and strategic implications for both companies as they seek to expand their market presence and technological capabilities.
More about TransThera Sciences (Nanjing). Inc.
TransThera Sciences (Nanjing), Inc. is a joint stock company based in China, focusing on the development of pharmaceutical products. The company is engaged in the research and development of innovative therapies, particularly in the area of NLRP3 inhibitors for treating multiple diseases.
Average Trading Volume: 2,615,117
Technical Sentiment Signal: Strong Buy
Find detailed analytics on 2617 stock on TipRanks’ Stock Analysis page.